TRend, a phase II trial, is analyzing the efficiency of palbociclib as monotherapy or in combination with ET in postmenopausal women with ER-positive, HER2-negative advanced breast cancer who have disease progression with previous therapy [36]. The gene discussed is ESR1; the disease is breast cancer.